Muichiro.T
Active member
In a new study, another plasma biomarker in Alzheimerās disease has been identified, the p-tau 217, in combination with amyloid 42/40, a blood test can accurately diagnose Alzheimerās disease with 90% sensitivity compared with 73%, in neurologists, and an impressively low 61%, in primary care physicians. This test assesses the levels of tau protein which refers to amyloid pathology that is critical in Alzheimerās diagnosis. Even though the test seems quite promising in terms of diagnosing the disease at an early stage and with high reliability, it is still not available for the practitioners of primary care. They are not a regular practice yet because more research and validation is still required. Meanwhile, lifestyle modifications and other preventive measures should still be practiced as a great help to cognition.